Real World Evidence of the Efficacy and Safety of FOQUEST
Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional
outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD
treated with FOQUEST or VYVANSE.